Relmada Therapeutics (RLMD) Competitors

$7.42 -0.07 (-0.97%)

Closing price 03:59 PM Eastern

Extended Trading

$7.42 +0.01 (+0.11%)

As of 04:04 PM Eastern

RLMD vs. DYN, ALMS, MOR, KLRA, and GPCR

Should you buy Relmada Therapeutics stock or one of its competitors? MarketBeat compares Relmada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relmada Therapeutics include Dyne Therapeutics (DYN), Alumis (ALMS), MorphoSys (MOR), Kailera Therapeutics (KLRA), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Relmada Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Dyne Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A

In the previous week, Dyne Therapeutics had 16 more articles in the media than Relmada Therapeutics. MarketBeat recorded 25 mentions for Dyne Therapeutics and 9 mentions for Relmada Therapeutics. Dyne Therapeutics' average media sentiment score of 0.89 beat Relmada Therapeutics' score of 0.20 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dyne Therapeutics' return on equity of -58.28% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Relmada Therapeutics	N/A	-157.81%	-135.88%

Dyne Therapeutics presently has a consensus price target of $35.21, suggesting a potential upside of 92.51%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 61.79%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Dyne Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Dyne Therapeutics beats Relmada Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Alumis?

Relmada Therapeutics (NASDAQ:RLMD) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Alumis has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 61.79%. Alumis has a consensus price target of $38.60, suggesting a potential upside of 56.72%. Given Relmada Therapeutics' higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alumis	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Relmada Therapeutics has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A
Alumis	$24.05M	130.27	-$243.32M	-$3.06	N/A

In the previous week, Relmada Therapeutics had 7 more articles in the media than Alumis. MarketBeat recorded 9 mentions for Relmada Therapeutics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.93 beat Relmada Therapeutics' score of 0.20 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -1,011.75%. Alumis' return on equity of -116.97% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-157.81%	-135.88%
Alumis	-1,011.75%	-116.97%	-88.43%

45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 40.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Relmada Therapeutics beats Alumis on 8 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to MorphoSys?

Relmada Therapeutics (NASDAQ:RLMD) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 61.79%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Relmada Therapeutics has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, Relmada Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Relmada Therapeutics and 0 mentions for MorphoSys. Relmada Therapeutics' average media sentiment score of 0.20 beat MorphoSys' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
MorphoSys	Neutral

Relmada Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Relmada Therapeutics' return on equity of -157.81% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-157.81%	-135.88%
MorphoSys	-226.79%	-694.31%	-22.55%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Relmada Therapeutics beats MorphoSys on 12 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Relmada Therapeutics (NASDAQ:RLMD) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kailera Therapeutics had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 11 mentions for Kailera Therapeutics and 9 mentions for Relmada Therapeutics. Kailera Therapeutics' average media sentiment score of 0.63 beat Relmada Therapeutics' score of 0.20 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 98.74%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 61.79%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kailera Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Kailera Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Relmada Therapeutics	N/A	-157.81%	-135.88%

Summary

Kailera Therapeutics beats Relmada Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Relmada Therapeutics compare to Structure Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Structure Therapeutics' return on equity of -24.91% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-157.81%	-135.88%
Structure Therapeutics	N/A	-24.91%	-23.67%

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 61.79%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 174.07%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Relmada Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its share price is 231% less volatile than the broader market.

In the previous week, Structure Therapeutics had 13 more articles in the media than Relmada Therapeutics. MarketBeat recorded 22 mentions for Structure Therapeutics and 9 mentions for Relmada Therapeutics. Structure Therapeutics' average media sentiment score of 1.29 beat Relmada Therapeutics' score of 0.20 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Structure Therapeutics beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$777.97M	$3.05B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-6.80	19.10	20.87	25.61
Price / Sales	N/A	278.05	521.62	63.45
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	6.29	4.36	9.86	6.71
Net Income	-$57.38M	$72.19M	$3.55B	$333.77M
7 Day Performance	-0.17%	-0.54%	-0.26%	0.40%
1 Month Performance	3.16%	0.31%	1.39%	4.03%
1 Year Performance	1,624.88%	46.31%	41.07%	36.33%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.8186 of 5 stars	$7.42 -1.0%	$12.00 +61.8%	+1,820.5%	$777.97M	N/A	N/A	10	News Coverage Earnings Report
DYN Dyne Therapeutics	3.5468 of 5 stars	$18.01 -2.4%	$35.14 +95.1%	+52.4%	$2.98B	N/A	N/A	100	Trending News Earnings Report Analyst Forecast Analyst Revision
ALMS Alumis	3.3917 of 5 stars	$23.07 -2.5%	$38.60 +67.3%	+457.4%	$2.93B	$24.05M	N/A	N/A
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
KLRA Kailera Therapeutics	4.9072 of 5 stars	$22.81 -0.5%	$42.75 +87.4%	N/A	$2.82B	N/A	N/A	145	News Coverage Analyst Forecast Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. DYN, ALMS, MOR, KLRA, and GPCR

How does Relmada Therapeutics compare to Dyne Therapeutics?

Summary

How does Relmada Therapeutics compare to Alumis?

Summary

How does Relmada Therapeutics compare to MorphoSys?

Summary

How does Relmada Therapeutics compare to Kailera Therapeutics?

Summary

How does Relmada Therapeutics compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. DYN, ALMS, MOR, KLRA, and GPCR

How does Relmada Therapeutics compare to Dyne Therapeutics?

Which has more volatility and risk, DYN or RLMD?

Which has higher earnings and valuation, DYN or RLMD?

Does the media refer more to DYN or RLMD?

Do insiders and institutionals have more ownership in DYN or RLMD?

Is DYN or RLMD more profitable?

Do analysts rate DYN or RLMD?

Summary

How does Relmada Therapeutics compare to Alumis?

Which has more risk and volatility, RLMD or ALMS?

Do analysts rate RLMD or ALMS?

Which has better earnings & valuation, RLMD or ALMS?

Does the media prefer RLMD or ALMS?

Is RLMD or ALMS more profitable?

Do institutionals and insiders hold more shares of RLMD or ALMS?

Summary

How does Relmada Therapeutics compare to MorphoSys?

Which has more risk and volatility, RLMD or MOR?

Do analysts rate RLMD or MOR?

Which has better earnings & valuation, RLMD or MOR?

Does the media prefer RLMD or MOR?

Is RLMD or MOR more profitable?

Do institutionals and insiders hold more shares of RLMD or MOR?

Summary

How does Relmada Therapeutics compare to Kailera Therapeutics?

Do institutionals & insiders hold more shares of KLRA or RLMD?

Does the media refer more to KLRA or RLMD?

Which has higher valuation and earnings, KLRA or RLMD?

Do analysts prefer KLRA or RLMD?

Is KLRA or RLMD more profitable?

Summary

How does Relmada Therapeutics compare to Structure Therapeutics?

Is RLMD or GPCR more profitable?

Do analysts prefer RLMD or GPCR?

Which has more risk & volatility, RLMD or GPCR?

Does the media prefer RLMD or GPCR?

Do institutionals and insiders believe in RLMD or GPCR?

Which has preferable earnings and valuation, RLMD or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools